Tag: RGS

Options Recap, 4 Fresh Ideas & More

Thursday’s Options Review: 

We’re ready to wrap up another trading week today, and it was a heck of solid one for us on the options front. We were bearish on most of our highlighted ideas for the day, and the markets took a serious dive in the second half of the session, which facilitated some kind gains. However, our one bullish target bucked the overall trend and delivered some notable intraday moves as well, so all in all it was a pretty good outing.

The winning targets that we were focusing our attention upon were the SIG Weekly $65-67 Calls, the BILI Weekly $27.50-26.50 Puts, and the NIO Weekly $20.50-19.50 Puts. The potential gains they yielded for the session were very respectable, and went as follows:

SIG Weekly $65-67 Calls
$65: 2.69-5.00 (+86%)
$66: 1.85-4.10 (+122%)
$67: 1.35-3.30 (+144%)
_____

BILI Weekly $27.50-26.50 Puts
$27.50: 1.24-2.65 (+114%)
$27: .80-2.18 (+173%)
$26.50: .60-1.88 (+213%)
_____

NIO Weekly $20.50-19.50 Puts
$20.50: 1.06-1.80 (+70%)
$20: .70-1.36 (+94%)
$19: .45-.95 (+111%)

Fresh Options Ideas:
BABA Weekly $110-113 Calls
DOCU Weekly $68-65 Puts
SPY 06/10 $400-398 Puts
SFIX Weekly $7-6.50 Puts

Extended Watchlist:
AHFD, ALMTF, MWWC, EBML, ITNS, TCRT, PALT, BRQS, NISN, RGS, BIMI

Blue Horseshoe Stocks: MMM Update & More

3M Co. MMM – Update

Fresh for yesterday morning’s report, we decided to highlight some MMM calls on the heels of the company’s earnings report, so we put the MMM Weekly $195-202.50 Calls on the radar.

Thanks to a solid intraday performance wherein the stock ran from a low of 194.20-199.89, there were some huge intraday moves from for traders to take advantage of promptly following the opening bell, which were as follows:

$195 Calls – Range: 2.24-6.00 – Max Gain: 168%
$197.50 Calls – Range: .67-4.34 – Max Gain: 548%
$200 Calls – Range: .71-2.80 – Max Gain: 294%
$202.50 Calls – Range: .27-1.55 – Max Gain: 474%

_____

Fresh Options Ideas:
AAPL Weekly $160-162.50 Calls
SPY Weekly $264-265.50 Calls


TrovaGene, Inc. TROV – Review

We last mentioned TROV on December 18th, and at the time the stock was trading down to an annual low of .503. Since then, we’ve seen a slow and steady recovery, which was kicked into a higher gear yesterday following news of Trovagene and PoC Capital entering an agreement to fund the development of Onvansertib in Metastatic Colorectal Cancer.

The stock ended up hitting .73, marking a 45% rise since we mentioned it. We will want to continue monitoring TROV for further advances from this point forward.

Extended Watchlist:
STAF, CREG, CRMD, EKSO, RGS, CLF, TOPS, WFT, ZYNE, IBN